MedicineNews.net - Medical Updates

TRK fusion cancer: updated analysis for Larotrectinib has confirmed high response rate and durable responses over three years in children and adults

Updated clinical data for Larotrectinib ( Vitrakvi ) in adult and pediatric patients with TRK fusion cancer showed a high response rate with an overall response rate ( ORR ) of 79% ( 95% CI: 72–85 ) w ... read article

ATLAS-2M trial: similar efficacy of Cabotegravir and Rilpivirine administered every eight weeks compared to four-week administration

Positive results from global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen ( 2DR ) of Cabotegravir and Rilpivirine for the treatment of HIV were announced. ... read article

Pooled five-year survival results for Nivolumab in previously-treated advanced non-small cell lung cancer patients

Long-term pooled efficacy and safety results from the phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer ( NSCLC ) were announced ... read article

5-year open-label treatment period: data have confirmed long-term efficacy and safety of Erenumab

During the OLTP ( open-label treatment period ), Erenumab ( Aimovig ) was not only able to reduce monthly migraine days, but also decrease the number of days requiring acute migraine-specific medicati ... read article

Adults with relapsing multiple sclerosis: Ponesimod reduces the annual rate of relapse

Results from the phase 3 OPTIMUM study, which evaluated the efficacy and safety of Ponesimod compared to Teriflunomide ( Aubagio ) in adults with relapsing multiple sclerosis were announced. The stud ... read article

Atopic dermatitis: effectiveness and safety of Dupilumab in a real-life French multicenter adult cohort

Dupilumab ( Dupixent ) is the first biologic available to treat atopic dermatitis. Its effectiveness and safety were demonstrated in clinical trials. Researchers sought to assess the effectiveness ... read article

Baricitinib, an oral JAK inhibitor, in combination with topical corticosteroids in adult patients with moderate to severe atopic dermatitis

Baricitinib ( Olumiant ) has met the primary endpoint in BREEZE-AD7, the third pivotal phase 3 trial in the BREEZE-AD program to be completed in 2019. BREEZE-AD7, an investigational study evaluatin ... read article

ELEVATE-TN trial: Acalabrutinib alone or in combination has significantly increased the time patients lived without disease progression

Results from the phase III ELEVATE-TN trial of Acalabrutinib ( Calquence ) in patients with previously-untreated chronic lymphocytic leukaemia ( CLL ), the most common type of leukaemia in adults, wer ... read article

Fingolimod is the first and only disease-modifying therapy with proven superiority versus Glatiramer acetate in relapsing remitting multiple sclerosis

Full data of the ASSESS study, which has evaluated the efficacy of oral, once-daily Fingolimod ( Gilenya ) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of Glatiramer acetate 20mg in r ... read article

Entrectinib in NTRK fusion-positive, locally advanced or metastatic solid tumours and metastatic, ROS1-positive non-small cell lung cancer

Entrectinib has shown efficacy in the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase ( NTRK ) fusion-positive, locally advanced or metastatic solid tumours wh ... read article

Dovato as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending marketing authorisation for Dovato, for the treatment of ... read article

COAST-X: Ixekizumab in patients with non-radiographic axial spondyloarthritis

Ixekizumab (Taltz ) has met the primary and all major secondary endpoints in COAST-X, a phase 3 study evaluating the safety and efficacy of Ixekizumab for the treatment of non-radiographic axial spond ... read article

Nonalcoholic steatohepatitis: combination of FXR agonist Cilofexor and ACC inhibitor Firsocostat

New data in nonalcoholic steatohepatitis ( NASH ) were presented at The International Liver Congress 2019 in Vienna. The data support the development of the combination therapies to target different ... read article

Long-term survival results from pooled analyses of Nivolumab in previously-treated non-small cell lung cancer patients

Results from pooled analyses of survival data from four studies ( CheckMate -017, -057, -063 and -003; n=664 ) in patients with previously-treated advanced non-small cell lung cancer ( NSCLC ) who wer ... read article

Kisqali plus Fulvestrant in women with HR+/HER2- locally advanced or metastatic breast cancer

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending an expanded indication for Kisqali ( Ribociclib ), the ... read article